Ani Pharmaceuticals Inc. | Small-cap | Healthcare
$63.56
-2.59%
| Ani Pharmaceuticals Stock Comparison:
Ani Pharmaceuticals vs ZoetisAni Pharmaceuticals vs Haleon Plc - ADRAni Pharmaceuticals vs SupernusAni Pharmaceuticals vs Indivior PLCAni Pharmaceuticals vs Bausch HealthAni Pharmaceuticals vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 614.4M
Gross Profit 364.2M 59.27%
Operating Income 2.2M 0.36%
Net Income -18.5M -3.01%
EPS (Diluted) -$1.04

Balance Sheet Metrics

Total Assets 1.3B
Total Liabilities 855.2M
Shareholders Equity 428.5M
Debt to Equity 2.00

Cash Flow Metrics

Operating Cash Flow 39.0M
Free Cash Flow 47.1M

Revenue & Profitability Trend

Ani Pharmaceuticals Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 614.4M 486.8M 316.4M 216.1M 208.5M
Cost of Goods Sold 250.2M 181.5M 138.8M 100.6M 87.2M
Gross Profit 364.2M 305.3M 177.6M 115.5M 121.3M
Research & Development 44.6M 34.3M 22.3M 11.4M 16.0M
Selling, General & Administrative 249.6M 161.7M 124.0M 84.3M 65.0M
Other Operating Expenses 67.7M 59.8M 57.0M 48.0M 55.9M
Total Operating Expenses 361.9M 255.8M 203.3M 143.7M 136.9M
Operating Income 2.2M 49.5M -25.7M -28.2M -15.6M
Pre-tax Income -22.2M 19.9M -62.7M -56.1M -26.0M
Income Tax -3.7M 1.1M -14.8M -13.5M -3.4M
Net Income -18.5M 18.8M -47.9M -42.6M -22.5M
EPS (Diluted) -$1.04 $0.85 -$3.05 -$3.40 -$1.88

Income Statement Trend

Ani Pharmaceuticals Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 527.7M 519.8M 344.3M 321.8M 170.3M
Non-Current Assets 756.0M 384.6M 415.8M 449.8M 290.9M
Total Assets 1.3B 904.4M 760.1M 771.6M 461.2M
Liabilities
Current Liabilities 193.7M 145.5M 99.4M 87.5M 78.6M
Non-Current Liabilities 661.5M 301.3M 322.1M 325.3M 186.9M
Total Liabilities 855.2M 446.8M 421.5M 412.9M 265.5M
Equity
Total Shareholders Equity 428.5M 457.6M 338.5M 358.7M 195.7M

Balance Sheet Composition

Ani Pharmaceuticals Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income -18.5M 18.8M -47.9M -42.6M -22.5M
Operating Cash Flow 39.0M 95.4M -37.6M 15.7M 9.1M
Investing Activities
Capital Expenditures -2.7M -8.9M -8.1M 92.0K -6.1M
Investing Cash Flow -404.0M -8.9M -8.2M -84.4M -6.1M
Financing Activities
Dividends Paid -1.6M -1.6M -1.6M -190.0K 0
Financing Cash Flow 258.5M 58.4M -6.6M 173.1M 5.4M
Free Cash Flow 47.1M 100.4M -47.7M -20.3M -53.1M

Cash Flow Trend

Ani Pharmaceuticals Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 51.63
Forward P/E 11.94
Price to Book 3.16
Price to Sales 2.12
PEG Ratio 11.94

Profitability Ratios

Profit Margin -3.12%
Operating Margin 7.61%
Return on Equity -4.57%
Return on Assets 0.83%

Financial Health

Current Ratio 2.66
Debt to Equity 142.03
Beta 0.55

Per Share Data

EPS (TTM) -$1.18
Book Value per Share $20.90
Revenue per Share $34.67

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
anip 1.4B 51.63 3.16 -4.57% -3.12% 142.03
Zoetis 70.3B 28.34 15.12 52.09% 27.12% 145.63
Haleon Plc - ADR 47.2B 25.01 5.88 8.95% 12.84% 63.41
Supernus 1.8B 28.53 1.72 6.32% 9.27% 3.13
Indivior PLC 1.7B 530.50 -6.04 -0.57% -5.30% -1.29
Bausch Health 2.3B -47.00 -9.23 14.29% -0.41% -89.63

Financial data is updated regularly. All figures are in the company's reporting currency.